S Vanden Branden

Statistics

Publications

Citations

H-Index

Active since

2018

Affiliations

AZ Delta(Current)

Imelda Hospital

Onze Lieve Vrouwziekenhuis Hospital

AZ Groeninge

Centre Hospitalier Universitaire de Liège

S Vanden Branden is an author at AZ Delta specializing in inflammatory bowel disease therapy, inflammatory bowel disease, and gastrointestinal pharmacotherapy.

Publications per year

2018–2023

Publications

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Peter Bossuyt, Filip Baert, F D’Heygere et al. · Inflammatory Bowel Diseases · 2018 · 32 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Saartje Van de Vondel, Filip Baert, C Reenaers et al. · Inflammatory Bowel Diseases · 2018 · 25 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study

Aurélien Amiot, Jean‐François Rahier, Filip Baert et al. · Journal of Crohn s and Colitis · 2022 · 14 citations · Full text

Medicine, Infectious Diseases, Clinical Epidemiology +10

Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study

Pauline Lemmens, Édouard Louis, Wouter Van Moerkercke et al. · Clinical Gastroenterology and Hepatology · 2023 · 13 citations · Full text

Life Sciences, Immunology, Inflammation +11

P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study

Anneline Cremer, Triana Lobatón, S Vieujan et al. · Journal of Crohn s and Colitis · 2020 · 10 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

1–5 of 5